National prescribing arrangements already allow for bisphosphonates to be prescribed for the prevention of secondary breast cancer. Decisions about funding for this use are rightly taken by local clinical commissioning groups which are best placed to know what local need exists.
The National Institute for Health and Care Excellence is currently updating its advice to the NHS on the diagnosis and management of early and locally advanced breast cancer. The use of bisphosphonates is included in its scope and will be considered as part of the update, which is expected in July 2018.
By Patrick McLoughlin on December 01, 2016